Accumulation of active metabolite M-2 predicts overall survival (OS) of chemorefractory metastatic colorectal cancer patients treated with regorafenib (REGO) Meeting Abstract
| Authors: | Rousseau, B.; Boukerma, A. K.; Henriques, J.; Cohen, R.; Lucidarme, O.; Borg, C.; Tournigand, C.; Kim, S. C. H.; Bachet, J. B.; Mazard, T.; Louvet, C.; Chibaudel, B.; Diaz, L. A.; Vernerey, D.; Andre, T.; Hulin, A. |
| Abstract Title: | Accumulation of active metabolite M-2 predicts overall survival (OS) of chemorefractory metastatic colorectal cancer patients treated with regorafenib (REGO) |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Start Page: | 178s |
| Language: | English |
| ACCESSION: | WOS:000487345805055 |
| DOI: | 10.1200/JCO.2019.37.15_suppl.3121 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 3121 -- Source: Wos |
